Pfizer Inc. ( PFE, Financial) rose to prominence during the Covid-19 pandemic for its rapid development of a vaccine and ...

Pfizer Canada ULC and BioNTech SE (Nasdaq: BNTX, "BioNTech") announced today that Health Canada has authorized the KP.2 ...

But the court ruled another similar patent was valid and that Pfizer and BioNTech’s Comirnaty vaccine had infringed it, ...

Pfizer and Moderna's legal battle over their rival COVID-19 vaccines will continue after London's High Court on Wednesday ...

Pfizer Canada says Health Canada has approved its updated COVID-19 vaccine that protects against one of the most recently ...

BioNTech's updated COVID-19 vaccine that protects against one of the most recently circulating variants of the virus. The ...

Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union ...

Pfizer's pandemic-fueled revenue surge, largely driven by Covid-19 products like Comirnaty, has now become a challenge as vaccine revenues sharply decline. In the second quarter, Comirnaty sales ...

The company's best days as a top pandemic vaccine supplier might be over, but it still has enough potential to be compelling.

The COVID-19 vaccines (COMIRNATY ®) by Pfizer and BioNTech are based on BioNTech’s proprietary mRNA technology and were developed by both companies. BioNTech is the Marketing Authorization ...

I feel that the sluggishness in Pfizer's stock price derives from investors expecting another Comirnaty, and being impatient that the company hasn't lately developed a new world-beating product.